MX2023001937A - Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento. - Google Patents

Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento.

Info

Publication number
MX2023001937A
MX2023001937A MX2023001937A MX2023001937A MX2023001937A MX 2023001937 A MX2023001937 A MX 2023001937A MX 2023001937 A MX2023001937 A MX 2023001937A MX 2023001937 A MX2023001937 A MX 2023001937A MX 2023001937 A MX2023001937 A MX 2023001937A
Authority
MX
Mexico
Prior art keywords
factor
monoclonal antibodies
human
compositions
pro
Prior art date
Application number
MX2023001937A
Other languages
English (en)
Inventor
Munehisa Yabuki
Yi Li
William Jason Cummings
Jeremy A Freeman
Kathleen A Shaffer
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of MX2023001937A publication Critical patent/MX2023001937A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se describen anticuerpos monoclonales que se unen específicamente al Factor D maduro humano y que no se unen al Pro-Factor D humano, anticuerpos monoclonales que se unen específicamente al Pro-Factor D humano y no se unen al Factor D maduro humano, y anticuerpos monoclonales que se unen tanto al Factor D maduro humano como al Pro-Factor D humano. También se describen métodos de uso de anticuerpos monoclonales y composiciones que comprenden los mismos, para la detección de la forma madura y/o pro del Factor D en muestras biológicas, para determinar el estado de la Vía Alternativa del Complemento (APC) en un sujeto mamífero, o para determinar el estado del Factor D después del tratamiento con un agente inhibidor de MASP-3 que inhibe la conversión de Pro-Factor D en Factor D maduro.
MX2023001937A 2020-08-18 2021-08-17 Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento. MX2023001937A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063066942P 2020-08-18 2020-08-18
US202063066948P 2020-08-18 2020-08-18
US202163197833P 2021-06-07 2021-06-07
PCT/US2021/046250 WO2022040149A1 (en) 2020-08-18 2021-08-17 Monoclonal antibodies, compositions and methods for detecting complement factor d

Publications (1)

Publication Number Publication Date
MX2023001937A true MX2023001937A (es) 2023-04-05

Family

ID=80269371

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001937A MX2023001937A (es) 2020-08-18 2021-08-17 Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento.

Country Status (11)

Country Link
US (1) US20220056117A1 (es)
EP (1) EP4199954A1 (es)
JP (1) JP2023538914A (es)
KR (1) KR20230047492A (es)
AU (1) AU2021328262A1 (es)
BR (1) BR112023002843A2 (es)
CA (1) CA3189666A1 (es)
CL (1) CL2023000476A1 (es)
IL (1) IL300704A (es)
MX (1) MX2023001937A (es)
WO (1) WO2022040149A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
WO2024097163A1 (en) * 2022-11-02 2024-05-10 Omeros Corporation Therapeutic methods and uses for antibodies to human masp-3

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CN102574915B (zh) * 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
US11603407B2 (en) * 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2020010235A1 (en) * 2018-07-05 2020-01-09 H. Lee Moffitt Cancer Center And Research Institute Inc. Car t cells that target b-cell antigens

Also Published As

Publication number Publication date
IL300704A (en) 2023-04-01
EP4199954A1 (en) 2023-06-28
KR20230047492A (ko) 2023-04-07
JP2023538914A (ja) 2023-09-12
CA3189666A1 (en) 2022-02-24
US20220056117A1 (en) 2022-02-24
AU2021328262A1 (en) 2023-03-16
CL2023000476A1 (es) 2023-09-22
WO2022040149A1 (en) 2022-02-24
BR112023002843A2 (pt) 2023-03-14

Similar Documents

Publication Publication Date Title
MX2023001937A (es) Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento.
WO2017139587A3 (en) Anti-dengue virus ns1 protein monoclonal antibodies
Mata et al. Effects of cryopreservation on effector cells for antibody dependent cell-mediated cytotoxicity (ADCC) and natural killer (NK) cell activity in 51Cr-release and CD107a assays
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
Błogowski et al. Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
CR20220646A (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
MX2020010387A (es) Metodos para detectar y cuantificar fgf21.
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
EA201590247A1 (ru) Антитела к siglec-15
EP1718768A4 (en) METHODS AND COMPOSITIONS FOR THE DETERMINATION OF TOLERANCE PHENOTYPE IN RESPECT OF GRAFFON IN A SUBJECT
EA200701600A1 (ru) Способ получения лёгкодоступного клеточного материала из периферической крови и композиция на его основе
Naranbhai et al. Impact of blood processing variations on natural killer cell frequency, activation, chemokine receptor expression and function
EP4273551A3 (en) Multiplexed total antibody and antibody-conjugated drug quantification assay
WO2008036835A3 (en) Methods and compositions for upregulation of peroxiredoxin activity
EA202090634A1 (ru) Антагонисты tim-3 для лечения и диагностики онкологических заболеваний
EA201390543A1 (ru) Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
MX2020001489A (es) Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano.
NZ599773A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2020006728A (es) Metodos para medir analito y/o proteina en muestras biologicas.
AR084263A1 (es) Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)
WO2010031749A9 (en) Compositions and methods for detecting tlr3
WO2019066617A3 (ko) 항 c-met 항체 및 이의 용도